Skip to content

Intubation of Morbidly Obese Patients. A Clinical Trial, Comparing Glide Scope ® With Fastrach TM

Intubation of Morbidly Obese Patients. A Randomized Clinical Trial, Comparing GlideScope ® With Fastrach TM.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01237080
Enrollment
100
Registered
2010-11-09
Start date
2010-09-30
Completion date
2011-01-31
Last updated
2013-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intubationattempts, Intubationtime, Morbidly Obese

Brief summary

The purpose of this study is to compare the GlideScope ® and the Fastrach TM for intubation of morbidly obese. Mainly we will try to clarify which of the instruments that produce the shortest intubationtime and lowest number of intubationattempts. The hypothesis is that intubation would be 1) quicker and 2) with the lowest number of attempts, using the GlideScope®.

Detailed description

The number of obese people rises. Thus 25.2% of Danish 9th graders are obese. As a result, surgery and anesthesia in obese patients becomes more frequent. Several potential problems related to anesthesia in this patient group exists, including airway management and sufficient oxygenation. Anaesthesia of obese patients are more likely to require intubation. In light of the foregoing, it is therefore important to find the methods that provide the fewest complications related to intubation. Therefore this study compare two instruments (Fastrach TM and GlideScope ®) to find out which of the methods that provides the best airway management, measured primarily in time and numbers of intubation attempts.

Interventions

DEVICEGlideScope

The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.

DEVICEFastrach

The Fastrach is an intubation laryngeal mask.

Sponsors

Glostrup University Hospital, Copenhagen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* BMI \>/= 35

Exclusion criteria

* need for crash induction.

Design outcomes

Primary

MeasureTime frameDescription
Number of Patients Intubated in the First Attemptplease see descriptionThe intubation attempt was considered a failure if the GS or the FT was removed from the patient's mouth and required reinsertion or if the cuff had been inflated and the tube needed to be replaced (e.g., in oesophageal intubation).
Time to IntubateFrom when the anaesthetist picked up the GS / FT until a typical capnogram was seen on the capnograph.

Secondary

MeasureTime frame
Subjectively Intubation Difficultymeasured immediately on a visual analogue scale.
Intubation of the Esophagus.detected immediately
Lowest Saturation During Intubation.measured on the monitor
Postoperative Throat Pain.one hour postoperative
Postoperative Hoarseness.one hour postoperative.
Mucosal Lesioninspection during intubation and one hour postop.

Countries

Denmark

Participant flow

Recruitment details

The study was conducted from September 2010 to January 2011. Patients were recuted from two hospitals.

Pre-assignment details

Exclusion: severe mental disorder, greater alcohol consumption than recommended by the Danish Health Authority, drug abuse, previously impossible mask ventilation or intubation with the GS and/or FT, the need for RSI and if the anaesthetist responsible determined that the patient should be treated differently than described in the protocol.

Participants by arm

ArmCount
Fastrach
50 persons beeing intubated using the Fastrach.
50
GlideScope
50 persons beeing intubated using the GlideScope.
50
Total100

Baseline characteristics

CharacteristicGlideScopeFastrachTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
50 Participants50 Participants100 Participants
Age Continuous43 years42 years42 years
FULL_RANGE 999999
Region of Enrollment
Denmark
50 participants50 participants100 participants
Sex: Female, Male
Female
43 Participants33 Participants76 Participants
Sex: Female, Male
Male
7 Participants17 Participants24 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 500 / 50
serious
Total, serious adverse events
0 / 500 / 50

Outcome results

Primary

Number of Patients Intubated in the First Attempt

The intubation attempt was considered a failure if the GS or the FT was removed from the patient's mouth and required reinsertion or if the cuff had been inflated and the tube needed to be replaced (e.g., in oesophageal intubation).

Time frame: please see description

ArmMeasureValue (NUMBER)
FastrachNumber of Patients Intubated in the First Attempt42 participants
GlideScopeNumber of Patients Intubated in the First Attempt46 participants
Primary

Time to Intubate

Time frame: From when the anaesthetist picked up the GS / FT until a typical capnogram was seen on the capnograph.

Population: The sample size was calculated to 40 in each group (50 patients were included in each group): minimum relevant difference in intubation time of 20 s and a standard deviation of 28 s. A significance level of 0.05 and an acceptable risk of Type 2 error of 0.1 were used.

ArmMeasureValue (MEAN)
FastrachTime to Intubate61 sec
GlideScopeTime to Intubate49 sec
Secondary

Intubation of the Esophagus.

Time frame: detected immediately

Secondary

Lowest Saturation During Intubation.

Time frame: measured on the monitor

Secondary

Mucosal Lesion

Time frame: inspection during intubation and one hour postop.

Secondary

Postoperative Hoarseness.

Time frame: one hour postoperative.

Secondary

Postoperative Throat Pain.

Time frame: one hour postoperative

Secondary

Subjectively Intubation Difficulty

Time frame: measured immediately on a visual analogue scale.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026